Key result
Higher CHA2DS2-VASC score (OR 0.90; 95% CI 0.45-0.95), older age, and higher deprivation were independently associated with fewer VKA prescriptions in stroke survivors with atrial fibrillation.
Why the study?
What are the sociodemographic associations with vitamin K antagonist prescription in stroke survivors with atrial fibrillation?
Cross-Sectional (n=3,429)
What are the sociodemographic associations with vitamin K antagonist prescription in stroke survivors with atrial fibrillation?
Odds Ratio: 0.9 (95% CI 0.45–0.95)
In a high-risk population of stroke survivors with AF, VKA anticoagulation was underused, with older age and higher deprivation independently associated with non-prescription.
May signal VKA undertreatment in higher-risk, older, and deprived AF stroke survivors; leaves open equity-focused prescribing interventions.
OBJECTIVE: To describe vitamin K antagonist (VKA) anticoagulation prescribing patterns in stroke survivors with atrial fibrillation (AF), with particular emphasis on sociodemographic associations with VKA prescription. METHODS: We conducted a cross-sectional analysis of city-wide Glasgow primary care data held as part of the Local Enhanced Services (LES) for the year 2010. We collated clinical and sociodemographic data of community-dwelling ischaemic stroke survivors with AF, including risk factors; comorbidity; socioeconomic status and prescribing. We described stroke risk and bleeding risk using recommended stratification tools (CHA2DS2-VASC and HAS-BLED). Univariate and multivariate associations with anticoagulant prescription were described by ORs and corresponding 95% CI. RESULTS: We identified 3429 community-dwelling, ischaemic stroke survivors with AF; median age 78 (IQR 72-84); 1699 (49%) male. Median CHA2DS2-VASC score was 5 (IQR 4-6). VKA was prescribed in 1165 (34%). On univariate analysis, higher CHA2DS2-VASC was associated with fewer VKA prescriptions (OR 0.90, 95% CI 0.45 to 0.95). On multivariate analysis, older age (OR 0.97, 95% CI 0.96 to 0.98) and higher deprivation scores (OR 0.59, 95% CI 0.57 to 0.76) were independently associated with non-prescription of VKA. CONCLUSIONS: Anticoagulation was underused in this high-risk population, and those at highest risk were less likely to be treated. Strategies need to be developed to improve prescription of anticoagulation treatment.
No takes yet. Share an insight, caveat, or question.
Abdul‐Rahim et al. (2014) conducted a cross-sectional in ischaemic stroke survivors with atrial fibrillation (n=3,429). Higher CHA2DS2-VASC score vs. Lower CHA2DS2-VASC score was evaluated on VKA prescription (OR 0.90, 95% CI 0.45-0.95). Higher CHA2DS2-VASC score (OR 0.90; 95% CI 0.45-0.95), older age, and higher deprivation were independently associated with fewer VKA prescriptions in stroke survivors with atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: